54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

AmpliPhi Biosciences to Conduct Clinical Trial With University of Adelaide

AmpliPhi Biosciences announced that it has signed a clinical trial agreement with the University of Adelaide to conduct a Phase 1 trial of bacteriophage therapy.

The trial will be focused on the treatment of infections caused by staphylococcus aureus, a common bacterium often found in the respiratory tract. The study will look at patients with chronic colds caused by staphylococcus aureus.

The single-site trial will be conducted at the Queen Elizabeth Hospital, Adelaide, Australia, and will be sponsored by the University of Adelaide.

“This Phase 1 clinical study represents a significant step for AmpliPhi on our mission to attack the rising menace of drug-resistant bacterial infections,” said M. Scott Salka, CEO of AmpliPhi. “We are proud to be working with Dr. Peter-John Wormald and the entire team at the University of Adelaide and the Queen Elizabeth Hospital to advance our novel bacteriophage-based therapy into the clinic and demonstrate the potential of phage therapy to provide relief to the millions of patients ravaged every year by antibiotic-resistant bacteria.”

AmpliPhi Biosciences Corp. (NYSEMKT: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corp. (NYSE: XON), the U.S. Army, The Royal Brompton Clinic in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies.

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-